THC and CBD actually are FTA approved. By Rhea Graham

Plants can’t be patented, so synthetic cannabinoids must be made for the pharmaceutical companies to make their prized money. That’s it in a nutshell for those who have asked about the status of FDA approval on Cannabis.
Of course it’s the synthetic pharmaceutical version you are forced to use, if using your insurance or in a state that doesn’t have a “Medical Marijuana” Program. Marinol is the brand name of the substance dronabinol. Dronabinol is synthetic THC and is used to treat cancer patients for nausea and vomiting caused by chemotherapy and to treat AIDS patients for appetite and weight loss. Marinol was approved by the FDA in 1985 and costs a pretty penny, yet Cannabis grows for pennies… there’s the biggest reason “REAL” THC and CBD haven’t been approved – GREED.
As an example, if you were to purchase sixty 2.5mg Dronabinol at Costco, it would cost you $81.25; the highest price listed is $164.93. If you were micro dosing with those, it would cost you as little as $4 a day at Costco, or as much as $8.25 per day at the “Medicine Shoppe” pharmacy. Those are just measly 2.5 mg of THC only. Just think if you needed 10 mg three times a day, your cost quickly triples. You can make them yourself for a much better price for a far higher quality product that your body wants, instead of a synthetic that your body does not want and does not like to process.
Epidiolex, the FDA approved CBD prescription medicine made by British drugmaker GW Pharmaceuticals, is essentially a stripped, isolated pharmaceutical-grade version of CBD oil. The side effects include diarrhea, vomiting, fatigue and sleep problems. Those side effects do not occur with full plant or “real” medicine.
To complete the story, you should know that the former FDA chief, Scott Gottlieb is the most recent reason the real plant isn’t FDA approved. Gottlieb “is also a physician who consults for and invests in biopharmaceutical companies. He joined Pfizer’s board of directors earlier this summer” according to an article on CNBC dated 9 August 2019. (Just a bit of conflict of interest).